{"analyses":[{"ciNumSides":"TWO_SIDED","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.0034","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.64","paramType":"Slope","paramValue":"0.0016","statisticalComment":"Adjusted for tumor type, baseline creatinine, prior SRE, prior bisphosphonates, age, gender, BSA, race, and baseline performance status","statisticalMethod":"Mixed Models Analysis"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.042","value":"0.82"},{"groupId":"OG001","spread":"0.042","value":"0.84"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"882"},{"groupId":"OG001","value":"884"}],"units":"Participants"}],"description":"To compare functional status (ECOG performance status) of patients with metastatic breast cancer, metastatic prostate cancer, or myeloma involving bone receiving every 12 week dosing of zoledronic acid to those receiving every 4 week dosing. The change scores were evaluated in a general linear model with repeated measures for treatment effect and the time trend with patient-specific characteristics being adjusted. Specifically the difference in score change per 4 weeks for Arm I using Arm II as the reference is reported. ECOG performance status is a measurement of a patients disability ranging from 0, fully active and able to carry out all pre disease performance without restriction, to 5, dead. The average performance status is reported below by arm.","dispersionType":"Standard Error","groups":[{"description":"Patients receive zoledronic acid IV over at least 15 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I (Zoledronic Acid Every 4 Weeks)"},{"description":"Patients receive zoledronic acid IV over at least 15 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm II (Zoledronic Acid Every 12 Weeks)"}],"paramType":"MEAN","populationDescription":"1766 patients completed treatment and were analyzed.","reportingStatus":"POSTED","timeFrame":"from baseline up to 2 years","title":"Average ECOG Performance Status","type":"SECONDARY","unitOfMeasure":"score on a scale"}